Dr.Rafael Béjar, a world expert in the study of myelodysplastic syndromes (MDS), visits the Josep Carreras Leukaemia Research Institute
"Treatment for patients with MDS is becoming more and more personalised. In the coming years we are going to see more emphasis on the genetic mutations associated with MDS. Every patient has a different pattern of mutations and these mutations can be used to indicate how the patient should be treated. The mutations can be used to establish the diagnosis, determine the prognosis and to predict which therapies will be the most efficacious."